Welcome to the e-CCO Library!

DOP10: Serum N-glycomic biomarkers predict treatment escalation in inflammatory bowel disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Archana Shubhakar
Created: Tuesday, 28 May 2019, 3:32 PM
Other
Files: 1
DOP10: Serum N-glycomic biomarkers predict treatment escalation in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Shubhakar*1, B. Jansen1, A. Adams2, K. Reiding3, N. Ventham4, D. Bergemalm5, P. Urbanowicz1, R. Gardner1, IBD-BIOM Consortium1, J. Halfvarson6, J. Satsangi2, D. Fernandes1, M. Wuhrer7, D. Spencer1

Created: Friday, 22 February 2019, 9:41 AM
DOP11 Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Plevris, J. Fulforth, P. Jenkinson, M. Lyons, C. Chuah, S. Siakavellas, R. Pattenden, I. Arnott, G. Jones, C. Lees

Created: Thursday, 30 January 2020, 10:12 AM
DOP11: A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease: A discovery and validation study in two independent inception cohorts
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Charlotte Bache-Wiig Mathisen
Created: Friday, 14 July 2023, 2:22 PM
DOP11: A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease: A discovery and validation study in two independent inception cohorts
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bache-Wiig Mathisen, C.(1,2)*;Nyström, N.(3);Bazov, I.(4);Andersen, S.(5);Olbjørn, C.(6);Perminow, G.(7);Kristensen, V.A.(1,8);Opheim, R.(1,9);Ricanek, P.(10,11);D`Amato, M.(12,13,14);Carlson, M.(15);Hedin, C.R.(16,17);Keita, Å.V.(18);Kruse, R.(19);Lindqvist, C.M.(20);Magnusson, M.K.(21);Salihovic, S.(22,23);Söderholm, J.D.(18);Öhman, L.(21);Repsilber, D.(4);Høivik, M.L.(1,2);Halfvarson, J.(24);
Created: Friday, 14 July 2023, 10:43 AM
DOP11: Early intestinal ultrasound predicts endoscopic response to anti-inflammatory treatment and shows drug-specific response to biologicals and tofacitinib in Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: de Voogd, F.(1);Bots, S.(1);Van Wassenaer, E.(2);De Jong, M.(1);Pruijt, M.(1);Löwenberg, M.(1);D'Haens, G.(1);Gecse, K.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP11: Fibrosis and MAGNIFI-CD activity-index at MRI to predict treatment outcome in perianal fistulising Crohn’s Disease patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Van Rijn, K.(1);Meima-van Praag, E.(2);Bossuyt, P.(3);D'Haens, G.(4);Horsthuis, K.(5);Snijder, H.(2);Tielbeek, J.(1);Buskens, C.(2);Stoker, J.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP11: Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in ulcerative colitis
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Stephanie Slevin
Created: Tuesday, 28 May 2019, 3:32 PM
Ulcerative colitis, Immunology, Lymphocyte, T cell
Files: 1
DOP11: Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Slevin*1, M. Tan1, C. Lahiff1, L. M. Wang2, B. Greenaway1, K. Lynch1, A. Geremia1, S. Hughes3, K. Leavens3, K. Nevin3, D. J. B. Marks3, R. Tarzi3, N. Srinivasan3, S. Travis1, C. Arancibia1, S. Keshav1

Created: Friday, 22 February 2019, 9:41 AM
DOP11: Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn's Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Nikolas Plevris
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Panaccione1, W.J. Sandborn2, B.E. Sands3, C. Marano4, C.D. O’Brien4, H. Zhang5, J. Johanns5, Y. Zhou5, L. Peyrin-Biroulet6, T. Hisamatsu7, S. Danese8, UNIFI Investigators

Created: Thursday, 30 January 2020, 10:12 AM
DOP12: Mutations in the X-linked inhibitor of apoptosis protein promote susceptibility to microbiota-induced intestinal inflammation
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Gopalakrishnan1,2, Y. Zeissig2, A. Strigli1, M. Basic3, J. Hartwig2, J. Wang4, M. Muders5, G. Barreton5, J. F. Baines4, A. Bleich3, J. Hampe1,5, S. Zeissig*1,2,5

Created: Friday, 22 February 2019, 9:41 AM
DOP12: Non-invasive assessment of intestinal inflammatory activity in Ulcerative Colitis by Multispectral Optoacoustic Tomography (MSOT)
Year: 2022
Source: ECCO'22
Authors: Klett, D.(1);Jesper, D.(1);Vitali, F.(1);Federle, A.(1);Atreya, R.(1);Strobel, D.(1);Leppkes, M.(1);Neufert, C.(1);Rath, T.(1);Neurath, M.F.(1);Waldner, M.J.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP12: Validation of a modified simple ultrasound activity Score for children with Crohn’s Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Ma, H.(1);Isaac, D.M.(1);Petrova, A.(1);Almeida, P.(1);Parsons, D.(1);Kuc, A.(1);Carroll, M.W.(1);Wine, E.(1);HuynhDr, H.(2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP12: Validation of radiomics features on MR enterography characterizing inflammation and fibrosis in stricturing Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sleiman, J.(1)*;Chirra, P.(2);Gandhi, N.(3);Gordon, I.O.(4);Viswanath, S.(2);Rieder, F.(5,6);
Created: Friday, 14 July 2023, 10:43 AM
DOP12: Validation of radiomics features on MR enterography characterizing inflammation and fibrosis in stricturing Crohn’s disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Joseph Sleiman
Created: Friday, 14 July 2023, 2:22 PM